Agile Therapeutics

Name

Agile Therapeutics

Legal name

Agile Therapeutics, Inc.

Website

https://agiletherapeutics.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Agile Therapeutics is a public pharmaceutical company that develops and commercializes FDA-approved transdermal hormonal contraceptive products, principally the weekly Twirla patch, for women of reproductive age in the United States.

Ownership category

akta.pro rank

Product category

Women's Contraceptive Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Contraceptive patches
• Hormonal contraception
• Transdermal drug delivery
• Women's health pharmaceuticals
• Prescription contraceptives

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Supply Chain, Personnel, Technology or R&D, Operations

Revenue model

1. Twirla Contraceptive Patch Sales: Revenue generated from sales of FDA-approved Twirla weekly contraceptive patch prescribed by healthcare providers and dispensed through pharmacies, with partnership with GoodRx/vitaCare to improve access and sales.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Core offering

Agile Therapeutics manufactures and sells Twirla, an FDA-approved weekly transdermal hormonal contraceptive patch delivering levonorgestrel and ethinyl estradiol to women of reproductive age with BMI less than 30 kg/m2. The patch is built on the company's proprietary SkinFusion five-layer matrix technology designed for adhesion, drug delivery, and wearability. The company is also developing pipeline candidates including AG200-15, AG200-ER, and AG890, all leveraging the SkinFusion platform.

Product overview

Agile Therapeutics offers a portfolio of transdermal contraceptive products anchored by its FDA-approved weekly hormonal birth control patch Twirla® (levonorgestrel and ethinyl estradiol), supplemented by its proprietary SkinFusion® Technology platform. All current and future product candidates utilize the SkinFusion five-layer patch technology. The product portfolio includes pipeline candidates AG200-15 (SmP) and AG200-ER (SmP), which are combined hormonal contraception formulations designed for shorter/lighter periods and extended-cycle regimens respectively, and AG890, a progestin-only contraceptive patch for women with specific health considerations. The company operates exclusively in the women's hormonal contraceptive space with transdermal delivery as its core technology focus.

Differentiator

Problem solved

Functional benefit

Brands

• Twirla: FDA-approved weekly hormonal birth control patch for women with BMI less than 30 kg/m2. Contains levonorgestrel and ethinyl estradiol.
• SkinFusion

Products and services

• Twirla® FDA-approved weekly hormonal birth control patch containing levonorgestrel and ethinyl estradiol, designed for women with BMI less than 30 kg/m2 who can become pregnant. Provides low-dose estrogen delivery via transdermal application, designed to maintain adhesion during water exposure.

Quantifiable outcome

• Reduced dosing frequency compared to daily oral contraceptives
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• vitaCare Prescription Services (GoodRx Holdings Inc)coreChannel Partner/ Reseller/ Distributor · 14 June 2023Partnership to expand access to Agile Therapeutics' Twirla contraceptive patch and grow Twirla's market presence. The collaboration aims to increase sales and contribute to the company's financial goals for 2023 by improving prescription access through GoodRx's pharmacy network.
• Carli LloydcoreGTM or Marketing PartnerBrand ambassador partnership with retired U.S. Women's National Team soccer star Carli Lloyd to generate awareness around women's health and empower women to understand their contraceptive options. Lloyd, a two-time Olympic gold medalist and two-time FIFA Women's World Cup champion, serves as brand envoy for Agile Therapeutics.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• TherapeuticsMD: TherapeuticsMD is a women's health pharmaceutical company focused on hormonal products including contraception and menopause therapies. It operates a similar branded women's health model with prescription-based commercialization.
• Organon & Co. Organon is a women's health-focused pharmaceutical company (spun out of Merck) with a broad portfolio spanning contraception (NuvaRing, Cerazette), fertility, and menopause. It is a direct competitor in women's reproductive health pharmaceuticals targeting similar prescribers and patients.
• Evofem Biosciences: Evofem Biosciences is a women's sexual and reproductive health company (Phexxi non-hormonal contraceptive). It directly competes in the U.S. contraceptive prescription market with a differentiated non-hormonal mechanism.
• Xulane (Mylan/Viatris): Xulane is the AB-rated generic weekly transdermal contraceptive patch, the only directly competitive product to Twirla. Both deliver levonorgestrel and ethinyl estradiol via a weekly patch and compete for the same prescription pool, though Xulane typically prices lower.

Broad incumbents

• AbbVie (Women's Health): AbbVie (including legacy Allergan) markets Lo Loestrin and other branded oral contraceptives. As a broad incumbent with deep women's health commercial infrastructure, it competes indirectly with Twirla in the branded hormonal contraceptive category.
• Bayer (Women's Health): Bayer is a global pharmaceutical incumbent with a leading women's health franchise (Mirena, Kyleena, Yaz, Beyaz). It competes broadly with Agile in contraception across hormonal IUDs and oral contraceptives with vastly greater resources and global reach.
• Pfizer (Women's Health): Pfizer is a global pharmaceutical leader with a broad women's health portfolio including contraceptive products. It competes as a broad incumbent rather than as a patch specialist.

Emerging players

• Daré Bioscience: Daré Bioscience is a clinical-stage women's health biopharmaceutical company developing contraceptives and other women's health products. It is an emerging competitor in the same therapeutic space, with overlapping target patients and prescribers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/agilether
• LinkedInlinkedin.com/company/agiletherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds17 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agile Therapeutics